Aktis Oncology Reports Key Pipeline Progress: AKY-2519 IND Cleared, AKY-1189 Granted Fast Track, Strong Cash Runway into 2029

summarizeSummary

Aktis Oncology's 10-K confirms FDA clearance for its second candidate AKY-2519 to enter Phase 1b trials, announces Fast Track designation for lead candidate AKY-1189, and reports a strong financial runway into 2029.

check_boxKey Events

• Second Candidate AKY-2519 Receives FDA IND Clearance

  The FDA cleared Investigational New Drug (IND) applications for both therapeutic [225Ac]Ac-AKY-2519 and imaging [64Cu]Cu-AKY-2519, allowing the company to proceed with a Phase 1b clinical trial for B7-H3 expressing tumors, expected to initiate mid-2026. This marks a significant advancement for the company's second pipeline program.

• Lead Candidate AKY-1189 Granted FDA Fast Track Designation

  The FDA granted Fast Track Designation to [225Ac]Ac-AKY-1189 for the treatment of locally advanced or metastatic urothelial cancer (UC) in patients who have progressed on prior systemic therapies. This designation aims to facilitate the development and expedite the review of the lead product candidate.

• Strong Liquidity Runway into 2029

  The company reported $226.8 million in cash, cash equivalents, and marketable securities as of December 31, 2025, supplemented by $335.3 million in net proceeds from its January 2026 IPO, providing sufficient capital to fund operations into 2029.

• Progress in Lead Program Clinical Trial

  Aktis Oncology has completed the first dose level of the Part 1 dose escalation for its Phase 1b clinical trial of [225Ac]Ac-AKY-1189 for Nectin-4 expressing tumors, with preliminary results anticipated in the first quarter of 2027.

auto_awesomeAnalysis

Aktis Oncology's annual report highlights significant advancements in its radiopharmaceutical pipeline and a robust financial position. The FDA clearance of Investigational New Drug (IND) applications for AKY-2519 (therapeutic and imaging) allows the company to advance its second product candidate into a Phase 1b clinical trial, expected to initiate mid-2026. This follows the recent news of the IND clearance, with the 10-K providing official confirmation and additional detail. Furthermore, the lead candidate, AKY-1189, received Fast Track Designation from the FDA for urothelial cancer, which could expedite its development and review process. The company also reported a strong cash position, with existing cash and IPO proceeds providing a liquidity runway into 2029, significantly de-risking near-term operations for this clinical-stage biotech. The ongoing Eli Lilly collaboration further validates its miniprotein radioconjugate platform.